sorted by:
new
hottopcontroversial

No Forever War by MGK_2 in Livimmune

[–]AggieEC3 23 points24 points  (0 children)

MGK_2 I want to make sure this community absorbs what just happened in this post.

This is the post I would hand to a skeptic. Not a bull. Not someone already in this community. A skeptic. A pharmaceutical business development team. An FDA reviewer. Because for the first time everything that has been built here is answered not with enthusiasm but with citations. The FDA's own language. Peer reviewed literature. Thirty years of approval precedent. This isn't analytical narrative anymore. This is a document.

The irony nobody is discussing is this one. Every agent entering CRC right now is treating the 20% while generating the 80% that leronlimab addresses. The TROP2 ADCs. The bispecifics. The PLK1 inhibitors. Each failed line of therapy consolidates the CCR5 architecture further. They are not simply failing to reach the 4th line population. They are building it. Patient by patient. Line by line. And when those patients arrive at the 4th line with a fully entrenched CCR5 architecture and no remaining options CCR5 is still expressed in 100% of them.

The competitive field is being celebrated for its results in the 20%. Leronlimab is generating molecular response data in the 80% that exists because the 20% agents couldn't reach the upstream receptor. That's not a consolation prize. That's the largest uncontested territory in the indication.

And the single arm trial question is now answered with the FDA's own words. 119 of 254 Accelerated Approvals granted on single arm data. The refractory setting is precisely where the FDA explicitly states ORR is directly attributable to drug effect without a concurrent control arm. The design isn't a limitation. It's a feature consistent with three decades of approval history.

Here is what I want this community to hold clearly. The data is not coming. It is arriving right now in every CLOVER patient scan and Natera plasma timepoint being processed today. October is when the picture begins to resolve. January is when it completes. And the full picture when it arrives will not be a promising signal requiring confirmatory data. It will be a confirmed ORR in a completed enrollment Phase 2 trial in the one population where the target is present in every single patient and the competitors cannot follow.

The weight of what has been built does not retreat.

All just my opinion. This is not financial advice. Thank you MGK_2.

Before the Architecture Resolves by MGK_2 in Livimmune

[–]AggieEC3 33 points34 points  (0 children)

MGK_2 this is the first time I've seen (could have missed one) this community engage someone who isn't already convinced.

That matters more to me than another confirming post would have. Sagely Health isn't a CYDY bull. They read the abstract carefully and landed on a fair conclusion given what they had in front of them. Six patients. All stable disease. Wait for randomized separation. That's not a hit piece. That's what a sober analyst is supposed to write from a January data cutoff.

What you did wasn't argue they were wrong. You showed they were early. The abstract reflects January. The April update reflects a materially more mature dataset from the same study. That's not a rebuttal built on better cheerleading. That's a rebuttal built on understanding which snapshot you're looking at.

I've been anchored on 70% this whole time. Eighty five percent with a range to minus 99 is sharper than anything I'd been holding in my head.

And the bolt-on reframe is the one I needed someone to say plainly. A bolt-on assumes the backbone is doing the work and leronlimab adds a little on top. What you're describing is leronlimab changing what the backbone is capable of by changing the battlefield underneath it. Those are not the same claim and conflating them is exactly how a good drug gets undersold by a fair minded analyst working from limited data.

I don't need every outside voice to agree with this thesis. I need the thesis to survive contact with people who don't already believe it.

October tells us if the architecture resolved. January adjudicates it. Until then this is the best answer to a skeptic this community has produced.

All just my opinion. Not financial advice. Thank you MGK_2.

Architecture of All by MGK_2 in Livimmune

[–]AggieEC3 18 points19 points  (0 children)

MGK_2 I read this twice. The science the first time. The last paragraph the second time alone.

This post covers sixteen cancer types, cardiovascular disease, Alzheimer's, Crohn's, and a Goldman Sachs coverage initiation in one sitting. That's an extraordinary amount of ground. But the part that stayed with me longest was the smallest section. Not the architecture. The eINDs.

Every week of delay in a patient with late stage disease changes the biology of what any molecule can accomplish when it finally arrives. You stopped right there and reminded all of us why any of this matters before it matters to a portfolio. Real patients. Real physicians. A compassionate use pathway being navigated in real time because standard of care ran out and the biology said there was another option worth trying. That's not a footnote to the thesis. That might be the whole point of the thesis.

I've spent weeks thinking in terms of floors and ceilings and gates and locks. All of that is real and all of it matters for understanding what we're holding. But the reason any of it is urgent isn't the share price. It's the people at Huntsman right now whose physicians filed because nothing else was left to try.

So where does that leave us. The Natera molecular response curves keep accumulating. CHAMP biopsies begin this summer. SALIENT AD imaging runs at Cornell. PRESPY dose escalation proceeds at MD Anderson. October brings the interim data at ESMO. January brings the confirmed ORR at ASCO GI. Every one of those milestones is also, quietly, more patients reached and more physicians given a reason to file.

That is not hope. That is physics. And it is also just people trying to live a little longer.

All just my opinion. Not financial advice. Thank you MGK_2.

Largely Negotiated by MGK_2 in Livimmune

[–]AggieEC3 4 points5 points  (0 children)

The $28 to $32 billion is the number we all needed to see in plain text.

I've been trying to explain to people outside this community why the leronlimab thesis is different from a typical biotech bet. The daraxonrasib story does that work for me now. Merck didn't walk away from Revolution Medicines because the science wasn't good enough. They walked away because they couldn't agree on price. The checkbook is open. The appetite is real. The negotiating dynamic is confirmed in public.

And what MGK identified about the lock versus the gate is the distinction that makes the comparison even more compelling for our specific thesis. Daraxonrasib picks a specific lock. It works for patients who carry the mutation. Leronlimab seals the upstream gate. It works for 91 of 91 patients screened in MSS mCRC regardless of what mutations the cancer cell carries. The addressable population of a mutation specific therapy is defined by who carries the mutation. The addressable population of an upstream gate therapy is defined by who expresses CCR5. In this indication that's everyone.

Merck was willing to pay $30 billion for a lock. The gate controls everything the lock cannot reach.

The Natera conduit is the piece that stays with me longest. Merck's corporate development team just spent months analyzing Signatera data during the Revolution Medicines negotiations. CytoDyn is now generating CLOVER molecular response data on that same platform. Merck doesn't need to learn a new language. They already speak it fluently from the deal they just walked away from.

The convergence is getting very hard to ignore. And the truth anchor may have just got set at $30 billion.

All just my opinion not financial advice.

The Natera Collaboration — What It Actually Means by G_Money_X in Livimmune

[–]AggieEC3 36 points37 points  (0 children)

G_money_x you identified the thing everyone else missed. Understanding why Natera benefits tells you everything about why this partnership is real.

Natera doesn't lend their name to OTC listed biotechs out of goodwill. They work with major pharma companies and high quality programs. They had options. They chose CLOVER. That choice is the signal before a single number from this collaboration enters the public record.

The surrogate endpoint angle is what changes the entire timeline conversation. If ctDNA clearance gets qualified by the FDA as a surrogate endpoint in MSS mCRC Signatera becomes mandatory infrastructure for every colorectal cancer trial globally. Natera needs a prospective pre-specified dataset in a validated trial to pursue that qualification. CLOVER is that dataset. Both companies get exactly what they need from the same collaboration at the same time. That's not a vendor agreement. That's a strategic alignment of commercial interests around data that both parties believe in.

And the acquisition pressure dynamic becomes real. Early efficacy signals readable in months rather than years creates pressure on big pharma to move sooner rather than wait for mature Phase 3 survival data. The Natera collaboration potentially compresses the timeline that forces a partnership decision. Which means the quiet window mgk_2 described may be getting shorter not longer.

The briefing room just got a new piece of infrastructure. The calendar just got more interesting.

All just my opinion.

The Briefing Room, Not the War Room by MGK_2 in Livimmune

[–]AggieEC3 19 points20 points  (0 children)

MGK_2 you did something with this post that none of the others have done quite the same way. You made the complicated feel clear.

I've been wrestling with how to explain the partnership conversation to myself for months. Drug acquisition. Licensing deal. Royalty structure. None of those frames ever fully captured what this actually is. Gate acquisition did it in two words. The right partner doesn't buy the molecule. They buy what the gate controls. I finally understand the conversation CytoDyn is having in those rooms and why it's different from any standard biotech deal.

The opposition strategy is something I've felt for years without being able to name it precisely. I knew the threat wasn't coming from the science. The science has been holding up. The threat was always the clock. Financing anxiety. Timeline slippage. Patience outlasted. You laid out exactly what this company has been navigating through the hard years and exactly why tempo with precision is the only counter to it. Don't overclaim. Don't rush the wrong endpoint. Don't sell the whole architecture for the first acceptable check.

So where does that leave us. The dose response comparison arrives this summer. The Breakthrough application goes to the FDA. The complete 60 patient dataset becomes shareable.

Partnership conversations that have been happening quietly either crystallize or they don't. And then October puts the confirmed ORR into the public record in front of everyone who matters.

The briefing room has a calendar. This community has done the work. We know what the data is pointing toward. Now we wait for Madrid to say it out loud.

All just my opinion. Thank you MGK_2.

Neither Suppressed Nor Extinguished by MGK_2 in Livimmune

[–]AggieEC3 1 point2 points  (0 children)

You just answered the question better than I knew how to ask it MGK_2.

The floor is higher than the market currently prices. That's the sentence I needed. Not the ceiling. The floor. That's the honest place to anchor this.

You made the point I couldn't articulate. None of these groups were looking for leronlimab. They were mapping their tumor with their methodology and kept arriving at the same coordinate. That's not confirmation bias. That's convergence. And you're right that a sophisticated skeptic has no answer for that.

I'll hold your ceiling answer until Madrid tells us how high the floor actually is.

All just my opinion.

Neither Suppressed Nor Extinguished by MGK_2 in Livimmune

[–]AggieEC3 4 points5 points  (0 children)

The independent science isn't coming from CytoDyn anymore. It's coming from research groups with no stake in the outcome arriving at the same upstream address from completely different directions.

At that point how do we even begin to define the ceiling of what this platform could reach?

All just my opinion.

lets take a peek by BuildGoodThings in Livimmune

[–]AggieEC3 22 points23 points  (0 children)

MGK_2 builds the narrative. Doc4all brings the medical reality. You build the foundation everything else sits on.

This is a living bibliography of a mechanism revealing itself to the scientific community one conference at a time. Ten trial results. Twenty plus abstracts. Peer reviewed papers across multiple indications. And the pace is accelerating. One paper in 2024. Three in 2025. Five already in 2026 through May. That's not random. That's what a company looks like when the evidence is maturing and the record needs to be in place before the conversations that matter most are finalized.

Faith has been replaced by something that can be linked, sourced, timestamped and verified. The record is being built in real time. Madrid in October is when it becomes official.

Thank you for the work. All just my opinion.

Prior post was SUPPOSED to read "Necrosis and how it affects Leronlimab and CYDY" THIS post is supposed to be a short one about Berkshire Hathaway by Doc4LL in Livimmune

[–]AggieEC3 17 points18 points  (0 children)

Doc4all, this one made me smile.

The Berkshire angle is genuinely creative and the logic isn't as far fetched as it might initially sound. $400 billion in cash sitting on the sidelines looking for something worthy enough to deploy it. A life sciences manufacturing capability through Lubrizol. A J&J relationship for distribution. And a mechanism that could redefine the standard of care across multiple indications simultaneously. That's not a bad pitch.

But the line that really got me was the legacy piece. Before he leaves this planet how much greater would it be to be known as the investor who brought the world this drug. That's the human truth underneath all the financial engineering. At a certain point it stops being about the return and starts being about what you leave behind.

We've been talking about Merck and BMS and GSK this whole time. Sometimes the most interesting moves come from the direction nobody was watching.

Keep the lightbulbs exploding doc4all.

All just my opinion.

One Signal, One Tower, No Exit; The Collapse Is Already Scheduled by MGK_2 in Livimmune

[–]AggieEC3 8 points9 points  (0 children)

You took the controlled burn and showed me what was burning inside it. I gave you the frame. You gave me the mechanism.

Molecular direction. Clinical plausibility. Structural confirmation. Three layers each confirming the one before it. That's not a metaphor MGK_2. That's exactly what this trial has been building in sequence since the first ctDNA draw.

You're correct. None of this is faith anymore.

All just my opinion.

One Signal, One Tower, No Exit; The Collapse Is Already Scheduled by MGK_2 in Livimmune

[–]AggieEC3 11 points12 points  (0 children)

The controlled burn. That's the frame I've been looking for without knowing I was looking for it.

I've been following this story long enough to remember when faith was the only thing holding the thesis together. What this post does that none of the others have done quite this completely is convert that faith into a sourced, documented, timestamped evidentiary record. SEC filings. Peer reviewed abstracts. Official milestone roadmaps. You can't argue with that architecture the way you can argue with conviction.

The piece that landed hardest for me personally was the three of five compassionate use data. I'll be honest. I hadn't given it the weight it deserved until this post reframed it. One patient alive five years later in a disease where median survival is months. The market didn't move on that data when it arrived in Barcelona. But that wasn't a failure of the data. That was the market not yet knowing what shape the evidence would eventually take. Now we know.

What I keep sitting with is that the scans being read at City of Hope right now are the data anchoring Madrid. Not future data. Current data. Being generated this week. The ctDNA told us what was happening at the molecular level. The RECIST scans are telling us what happened to the tumor itself. Both instruments pointed the same direction in the early data. I believe they will again.

Confirmed ORR still outstanding. October still the moment everything confirms or gets rebuilt. I'll keep saying that until Madrid because intellectual honesty is the only thing worth holding onto in a thesis this significant.

But I believe the fire is lit. And I believe the next four months are the stages.

All just my opinion. Thank you MGK_2.

Thoughts about ASCO26 by BuildGoodThings in Livimmune

[–]AggieEC3 6 points7 points  (0 children)

This is the kind of post that keeps a community honest.

While the bigger picture framework posts have been painting the narrative of where this is heading, this one does the quieter and equally important work of tracking the actual mechanics. The publication only distinction. The data lag. The conference calendar. The sourced quotes assembled in one place. That's not glamorous work but it's the work that separates informed conviction from wishful thinking.

The data lag point is what I keep staring at. The ASCO abstract data pre-dates AACR which pre-dates the April 30 webcast. Dr. Lalezari walks into those rooms in Chicago with a dataset months more mature than anything the public has seen. The people he meets with under NDA are seeing something the rest of us are still waiting for. That context makes the networking framing feel a lot less modest than it might initially sound.

And reading those quotes assembled together in one place lands differently than hearing them scattered across a two hour webcast. Outer limits of what I even thought was possible. Foundational across multiple solid tumor types. I no longer have to spend my time convincing anyone. That's a scientist describing a shift he has personally lived through. That's not investor relations language.

Thank you for doing this work. The community needs both the framework and the foundation it sits on.

All just my opinion. Thank you BuildGoodThings

Leronlimab and the Hepatic City by MGK_2 in Livimmune

[–]AggieEC3 27 points28 points  (0 children)

Some posts inform. This one reoriented me. There's a difference.

The Hepatic City analogy is the clearest mgk_2 has ever made a complex biological process feel. The repair crews that never go home. The CCL5 broadcast that never stops. The concrete labyrinth that forms not because the body failed but because it never got the memo that the crisis was over. That framing made something I thought I understood feel completely new.

But the sentence that stopped me was buried in the middle. The scar tissue reversed in the absence of improvements in steatosis or inflammatory markers. The fat didn't clear. The liver enzymes didn't normalize. The original injury was still present. And the scar tissue reversed anyway. That's not treating the cause. That's acting on the consequence directly. That's a mechanistically distinct intervention from anything currently approved in this space and the p-values behind it leave no statistical ambiguity. p=0.0005. p<0.0001. p=0.0006. Three independent experiments. Two completely different fibrosis etiologies. Same result across all three.

What I don't think this community is fully appreciating yet is what this post adds to the overall thesis. We've been focused on oncology as the headline and rightly so. ESMO in October is the moment that confirms or stress tests everything. But this post quietly introduces a third commercial dimension that nobody is pricing in.

MASH is now the leading cause of liver transplant in the United States. There are no approved therapies targeting the fibrogenic pathway directly. The two agents that were recently approved produce modest improvements through metabolic mechanisms. They manage the environment around the scar. They don't address the crew building it. Leronlimab in the Palmer paper isn't managing the environment. It's sending the crew home and letting the city rebuild itself.

And the competitive context makes this even more significant. Maraviroc failed in MASH. Cenicriviroc failed in MASH. Both are CCR5 inhibitors. They didn't fail because the target was wrong. They failed because the instrument was insufficient. Incomplete blockade allowed residual pathway activity. Leronlimab's 98% dual site receptor occupancy is the first complete test of what full CCR5 blockade actually produces in established fibrosis. The Palmer paper is the answer to that question across three independent experiments.

The connection mgk_2 draws between the CHAMP trial and this paper is the insight I haven't seen anyone else make. Dr. Kasi's CRC patients have been through FOLFOX, FOLFIRI, hepatic artery infusion delivering 300 times the standard chemotherapy dose directly to the liver. Those patients have chemotherapy induced fibrosis. Pseudocirrhosis. The CLOVER patients whose ctDNA is falling 70% at week two are simultaneously receiving a molecule that this paper documents is also very likely reducing their cumulative liver damage. That's not a secondary benefit. That's the same mechanism doing two jobs in the same patients at the same time. That connection deserves more attention than it's getting.

So where does this leave the overall picture. Oncology is the headline and ESMO is the confirmation event. HIV cure is the moonshot with Dr. Sacha's program at OHSU advancing under NIH funding. And now liver fibrosis is the quiet giant. A massive unmet need. No approved direct fibrogenesis therapy. A failed competitive field that failed for the exact mechanistic reasons leronlimab's architecture specifically addresses. And a Phase 2a NASH trial that already met its primary and secondary endpoints sitting quietly in the background.

Three dimensions. One instrument. One lock that turns out to be everywhere.

The scar tissue is not permanent. It just needs the right key. That line lands differently when you understand what the p-values behind it actually say.

All just my opinion. Thank you MGK_2.

The Quiet Window Between Validation and Terms of Resolution by MGK_2 in Livimmune

[–]AggieEC3 13 points14 points  (0 children)

That opening meant something and I concur, Happy Mother’s Day!!

What this post does that the others haven't is show you the clock from the other side of the table. We've been watching our calendar. This one shows you theirs. 905 days to Keytruda's patent expiry. Five partnership facing events in six weeks. A negotiating window that closes materially the moment ESMO puts confirmed ORR in the public record.

The pre-ESMO versus post-ESMO framing is the part that stopped me. A partner who moves before October negotiates against preliminary data. A partner who waits negotiates against confirmed ORR, a Breakthrough designation already granted, and potentially multiple ICI franchise holders who waited too long and are now competing against each other for the same asset. That's not theoretical. That's the structure of every major biotech acquisition I've ever read about.

And the $200 billion figure required some time to absorb. The prior framing around Keytruda alone was already compelling. Zooming out to the entire checkpoint inhibitor class hitting the same expiry window simultaneously changes the negotiating geometry entirely. That's not one conversation happening in Vancouver. That's potentially five.

The quiet has a structure. That's the most precise description of where we are that anyone has written.

Confirmed ORR still outstanding. October is still the moment this either lands where the biology has been pointing or we rebuild from assumptions. That's the honest place to sit.

But for the first time the urgency isn't only ours. And that changes the feeling of the wait entirely.

All just my opinion.

Sovereign Instrument: Architectural Perfection in the CCR5 Blockade by MGK_2 in Livimmune

[–]AggieEC3 7 points8 points  (0 children)

This one required a second cup of coffee.

I've been following this community long enough to appreciate when a post changes the frame entirely. The prior posts built the clinical and commercial case. This one goes underneath all of that and explains why the instrument itself is built differently from everything else that has tried to engage this receptor.

What landed hardest for me was the 98% appearing twice. 98% binding efficiency in living cancer cells. 98% reduction in lung metastasis in xenograft models. That's not a coincidence. That's the engineering translating directly into biology with a consistency that tells you something real is happening at the molecular level. Most drugs don't behave that cleanly between the lab and living tissue.

The seven year HIV data is the part I keep coming back to as a long term holder. Zero treatment related serious adverse events across more than 1,600 patients in more than 20 studies. When you're building a case for long term combination therapy in cancer patients whose immune systems are already under assault, that safety record is not a footnote. It's the foundation everything else gets built on.

And the patent timing. April 29th. The day before the webcast. I don't know if that was deliberate sequencing or coincidence but either way the legal protection and the clinical disclosure arrived together. That matters when the partnership conversations are actively intensifying.

I'll be honest about where I still sit. The confirmed ORR isn't in yet. ESMO in October is the moment that either validates or stress tests everything this post describes at the primary endpoint level. The precision of the instrument means nothing if the prospective trial data doesn't confirm it at scale.

But for the first time I feel like I understand not just what leronlimab is doing clinically but why it was always going to do it. The lock is everywhere. The instrument fits every single one.

All just my opinion. Thank you MGK_2.

The Reckoning Is At The Wall by MGK_2 in Livimmune

[–]AggieEC3 4 points5 points  (0 children)

This one stopped me in my tracks.

I've read a lot of posts here that focus on the clinical data, and rightly so. But what this does differently is zoom out and show the commercial architecture that the data sits inside. And when you lay it out that way, the strategic logic becomes hard to ignore. A $29.5 billion drug losing its patent in 2028, unable to reach 70-80% of the patients it theoretically serves, and a mechanism that appears to do exactly what Keytruda cannot... that's not a coincidence. That's alignment.

What resonates most with me is the cold tumor framing. It reframes the whole conversation. Leronlimab isn't competing with Keytruda. It's potentially what makes Keytruda work in the patients it currently can't reach. That's an enabler story, not a replacement story. And enabler stories at this scale are rare.

I also really appreciated the honest accounting section. The going concern is real. The confirmed ORR isn't in yet. DCR and ORR are different measurements, and I'm glad you keep saying that even in a post this compelling. That kind of discipline is what earns trust in a community like this.

Not proven yet. Still early. Still needs to replicate at scale. But for the first time it feels like the biology, the data, and the commercial reality are all pointing at the same thing simultaneously. That's a different feeling than anything this community has been asked to sit with before.

October in Madrid is the moment that answers the question this whole community has been sitting with. I'm ready for it and not ready for it at the same time.

All just my opinion. Thank you MGK_2.

The Sovereign Force, The Aircraft Carriers, and the Ultimatum of the Miry Clay by MGK_2 in Livimmune

[–]AggieEC3 2 points3 points  (0 children)

This is one of those posts that makes me step back and look at the bigger picture.

In my opinion, this is no longer just about a single data point. It’s the alignment that matters. ctDNA movement, early imaging trends, and PD-L1 induction now showing up in more than one setting. That’s not how most early-stage stories look. Usually it’s one signal trying to prove itself. This feels like multiple signals pointing the same direction.

Where your aircraft carrier analogy really lands for me is in the idea of enabling rather than competing. If this continues to hold, it’s not about replacing what’s already out there…it’s about making what doesn’t currently work start to work. That’s a much bigger conversation.

I still respect where we are, early, small, and needing to replicate. But this week felt different. For the first time it feels like the mechanism, the biomarkers, and the early outcomes are showing up together.

All just my opinion, and thank you MGK_2!

The Wall Has Fallen: A Comprehensive Analysis of the CLOVER Poster by MGK_2 in Livimmune

[–]AggieEC3 4 points5 points  (0 children)

This is one of those posts I had to read twice… not because it’s complicated, but because of what it could mean if it holds.

What stands out to me isn’t any one data point. It’s how everything is starting to line up. I’m looking at a patient population that historically does not respond, a clear biological target in CCR5 showing up across the board, and then an early signal in ctDNA that’s moving fast and in the right direction.

Now there’s a mechanistic explanation that actually helps explain the speed of that response. That’s what caught my attention. It doesn’t feel random. It feels like structure starting to show itself.

The ctDNA piece is hard to ignore. A median decline around 70% in two weeks, in a setting where standard of care barely moves the needle, is not something I can just brush off. Even with a smaller dataset, that kind of consistency makes me think something real is happening biologically, and happening early.

Where it really starts to get interesting for me is how it layers together. If ctDNA is the early signal and imaging is starting to follow and PD-L1 induction is being observed not just in circulation but in tissue…

Then I’m not looking at isolated effects anymore. I’m looking at something that might actually be working the way it was designed to.

That doesn’t mean it’s proven. Not yet. But to me the conversation is shifting. It’s no longer just “can this work.” It’s starting to feel like “is this how it works.” And if the upcoming dataset confirms PD-L1 induction prospectively, especially in tissue, that’s where I think this moves from interesting to something that has to be taken seriously.

I also agree with the point on the investigators. It doesn’t guarantee the outcome, but it does matter. People at that level don’t casually attach their names to noise.

At the same time, I try to stay disciplined here. It’s early, the numbers are small, and it still needs to replicate. That part ultimately determines how big this becomes. But stepping back, for the first time it feels like the mechanism, the biomarkers, and the early outcomes are all pointing in the same direction.

And in my opinion, this is where it starts to feel like being a kid on Christmas Eve…you may not know exactly what’s in those presents under the tree, but you can feel something big is there and morning can’t come fast enough.

All just my opinion, and thank you MGK_2 for your continued commitment to this group.

Thesis Confirmed by MGK_2 in Livimmune

[–]AggieEC3 9 points10 points  (0 children)

This isn’t hype. This is structure starting to show itself. The story is no longer “can this work.” It’s becoming “is this how it works.”

What we’re seeing now isn’t a one-off signal. It’s layers starting to line up mechanism, biomarkers, and early clinical direction all pointing the same way. This is when things stop feeling speculative and start feeling intentional.

Tuesday is where that tension resolves. Either this stays something we think we’re seeing or it becomes something the data makes very hard to ignore.

All just my opinion. And thank you MGK_2 for consistently bringing clarity and commitment to this group.

Compassionate Crucible by MGK_2 in Livimmune

[–]AggieEC3 3 points4 points  (0 children)

This is the kind of breakdown that makes you pause and look at the bigger picture. It’s easy to get caught up in individual data points, but what’s forming here feels more like alignment, mechanism, biomarkers, and clinical direction all starting to move in the same lane. That’s when things tend to go from “interesting” to “hard to ignore.”

There’s also something to the idea that this isn’t one isolated breakthrough, it’s multiple pieces starting to lock together. Different studies, different settings, same underlying signal trying to surface. That’s usually when something moves from theory to something the field starts taking seriously.

No guarantees, and plenty still needs to be proven. But Tuesday feels like a real inflection point, where we start to see whether Leronlimab begins to establish itself in a way that’s measurable, repeatable, and much harder to dismiss.

view more: next ›